Compare ZNB & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZNB | TIVC |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | China | United States |
| Employees | 14 | N/A |
| Industry | Engineering & Construction | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.6M |
| IPO Year | N/A | 2021 |
| Metric | ZNB | TIVC |
|---|---|---|
| Price | $1.75 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 110.8K | 63.1K |
| Earning Date | 11-12-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.75 |
| 52 Week High | $9.78 | $13.20 |
| Indicator | ZNB | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 58.44 |
| Support Level | $1.41 | $0.79 |
| Resistance Level | $2.08 | $1.21 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 31.65 | 67.91 |
Zeta Network Group is an entertainment technology company with a network that focuses on the application of technology and artificial intelligence in the entertainment industry. It provides online entertainment performances and online education through its wholly-owned subsidiaries Color Metaverse and CACM. The curriculum developed by the company includes music, sports, animation, painting and calligraphy, film and television, and life skills, covering various aspects of entertainment, sports, and culture.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.